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Abstract The central nervous system has been proposed as a
sanctuary site where HIV can escape antiretroviral control and
develop drug resistance. HIV-1 RNA can be at higher levels in
CSF than plasma, termed CSF/plasma discordance. We aimed
to examine whether discordance in CSF is associated with low
level viraemia (LLV) in blood. In this MRC-funded multicentre
study, we prospectively recruited patients with LLV, defined as
one or more episode of unexplained plasma HIV-1 RNAwithin
12 months, and undertook CSF examination. Separately, we
prospectively collected CSF from patients undergoing lumbar
puncture for a clinical indication. Patients with durable suppres-
sion of viraemia and no evidence of CNS infection were iden-
tified as controls from this group. Factors associated with CSF/
plasma HIV-1 discordance overall were examined. One hun-
dred fifty-three patients were recruited across 13 sites; 40 with
LLVand 113 undergoing clinical lumbar puncture. Seven of the
40 (18 %) patients with LLV had CSF/plasma discordance,
which was significantly more than 0/43 (0 %) with durable
suppression in blood from the clinical group (p= 0.005).
Resistance associated mutations were shown in six CSF sam-
ples from discordant patients with LLV (one had insufficient
sample for testing), which affected antiretroviral therapy at sam-
pling in five. Overall discordance was present in 20/153 (13 %)
and was associated with nadir CD4 but not antiretroviral con-
centrations in plasma or CSF. CSF/plasma discordance is ob-
served in patients with LLVand is associated with antiretroviral
resistance associated mutations in CSF. The implications for
clinical practice require further investigation.
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Introduction
The central nervous system (CNS) has been proposed as a
sanctuary site where HIV-1 replication may continue during
stable antiretroviral therapy (ART). Concentrations of many
antiretrovirals (ARVs) in cerebrospinal fluid (CSF) fall below
the minimum inhibitory concentration for wild type virus, and
there is large inter-individual variability in CSF penetration
(Letendre et al. 2010b; Vissers et al. 2010; Best et al. 2012;
Peluso et al. 2012; Ciccarelli et al. 2013; Cusini et al. 2013).
ARVs may also have reduced activity in some of the cell
populations that are susceptible to HIV infection in the CNS
(Aquaro et al. 2002; Gray et al. 2013). HIV-1 RNA can be
found at higher concentrations in CSF than in plasma in some
patients (Eden et al. 2010; Rawson et al. 2012), termed CSF/
p l a sma d i s co rd ance , wh i ch may r e su l t i n t h e
compartmentalised detection of drug-resistant variants in
CSF (Cunningham et al. 2000; Venturi et al. 2000; Strain
et al. 2005).
Unexplained intermittent or persistent low-level viraemia
(LLV) in plasma is a common clinical problem, occurring in
up to a quarter of ART-treated patients (Doyle and Geretti
2012). The source of this virus is not clear and the clinical
significance of LLV is debated (Doyle and Geretti 2012;
Doyle et al. 2012). Whether the CNS can act as a sanctuary
site for HIV-1 infection in these patients is not known. In this
MRC-funded multicentre prospective study, we aimed to in-
vestigate the occurrence of CSF/plasma discordance in pa-
tients with LLV compared to patients with durable suppres-
sion of HIV-1 RNA in blood. We also aimed to investigate
factors associated with CSF/plasma discordance, including
ARV concentrations and resistance-associated mutations
(RAMs) in the CSF.
Methods
Study population
We prospectively recruited HIV-1 positive adults (≥18 years)
receiving ART from 13 centres in the UK. Written informed
consent was obtained from all participants. The study was
approved by the North Wales Research Ethics Committee
(Central and East).
Patients were recruited in two groups. In the first group,
patients with LLV underwent lumbar puncture (LP) for re-
search purposes. LLV was defined as at least one episode of
unexplained plasma HIV-1 RNA viraemia above detection
threshold (40 copies/ml) within the previous 12 months. No
upper limit was specified. We included patients with blips and
persistent LLV. We excluded those with an alternative expla-
nation for virological non-suppression such as adherence
<95 % on self-report or recent commencement of ART.
Recent modification of ARTwas not an exclusion.
It was not considered ethically justifiable to perform re-
search LP on aviraemic controls without neurological symp-
toms; therefore, we prospectively recruited patients undergo-
ing LP for a clinical indication and collected extra CSF at the
time of LP. From this group, we identified patients with dura-
ble suppression of HIV-1 RNA detection limits (40 copies/ml)
over the past year and no evidence of CNS infection to act as
controls for those with LLV.
In a separate analysis, we examined factors associated with
discordance in the two groups combined, including patients in
the clinical group that were not durably suppressed or had
evidence of CNS infection.
Laboratory testing
Virology testing and quantification of drug concentrations
were performed centrally at the University of Liverpool.
CSF cell count, protein and glucose measurements and micro-
biological investigations were performed by routine methods
at the centres of care. In the LLV group, CSF cell count was
performed locally at the discretion of the treating physician.
Virology testing
HIV-1 RNA was measured centrally in simultaneous plasma
and CSF samples by the Abbott RealTime HIV-1 assay
(Maidenhead, UK) with a lower limit of quantification of 40
copies/ml, as previously described (Garcia-Diaz et al. 2013).
CSF/plasma discordance was defined as CSF HIV-1 RNA
levels >0.5 log10 higher than those in plasma based on criteria
from other studies (Rawson et al. 2012), and our own work
showing raised CSF inflammatory cytokines at this degree of
discordance (Nightingale et al. 2016). Discordant samples
underwent Sanger (population) sequencing of reverse tran-
scriptase (RT, amino acids 1 to 335), protease (amino acids 1
to 99) and integrase (amino acid 1 to 288) to detect RAMs, as
previously described (Stockdale et al. 2015).
Drug concentrations
ARV concentrations were determined in CSF and plasma by
liquid chromatography-tandem mass spectrometry (LC-MS/
MS). Drugs were extracted by protein precipitation (plasma)
or directly injected (CSF). Standard curves were made up in
artificial CSF (Harvard Apparatus, Holliston, MA, USA), and
matrix effects assessed by post column injection. Assays were
validated against repeated runs of quality controls (inter and
intra-assay variability) and external quality assurance
standards.
The revised CNS penetration effectiveness (CPE) score
(2010) was calculated by assigning a predefined number of
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points to each component of the ART regimen, as proposed by
Letendre et al. (Letendre et al. 2008, 2010a). Medication ad-
herence was assessed using the modified medication adher-
ence self report inventory (MASRI) questionnaire at the time
of LP.
Cognitive screening tools
In order to screen for issues related to cognitive impairment,
patients with LLV underwent assessment with the following
tools. Symptoms of cognitive difficulties were assessed by
asking patients to answer whether they had problems with
memory, reasoning and attention, as described by Simioni
et al. (Simioni et al. 2010), and used in international guidelines
(European AIDS Clinical Society 2014) [21] [21] [20] 20.
Patients were considered to have cognitive symptoms when
answering Byes, definitely^ on at least one of the three ques-
tions. Patients were also screened for cognitive impairment
using the International HIV Dementia scale (Zipursky et al.
2013). This scale uses three brief tests to assess motor speed,
psychomotor speed and memory-recall. A score of less than
ten has been considered potentially abnormal (Sacktor et al.
2005). Functional impairment was measured using the
Instrumental Activities of Daily Living scale (Heaton et al.
2004; Mind exchange 2013). The maximum score of eight
means no impairment in the following activities: telephoning,
shopping, preparing food, housekeeping, laundry, travel, med-
ications and finances. A score of seven or less indicates po-
tential functional impairment. Mood disorders were assessed
using the Hospital Anxiety and Depression scale, addressing
depressive (HAD-D) and anxious (HAD-A) symptoms sepa-
rately. Patients were considered depressed or anxious if the
HAD-D or HAD-A subscale score was at least ten out of 21
(Savard et al. 1998, 1999). Cognitive testing was not per-
formed in the clinical group as this could be confounded by
intercurrent illness.
Statistical analysis
Mann-Whitney U test was used to compare continuous non-
parametric variables. Fisher’s exact and chi-squared tests were
used for categorical data. The geometric mean of log10 ARV
concentrations in plasma and CSF was compared between
discordant and non-discordant patients with Student’s t test
and also combined with time post dose in a multivariate logis-
tic regression analysis using the forced entry method. A p
value of 0.05 was used to determine statistical significance.
When correlating CSF and plasma HIV-1 RNA, levels below
detection were assigned an arbitrary mid-point value between
zero and the 95 % detection rate. All analyses were performed
using SPSS v22.
Results
Study population
A total of 153 ART-treated patients were recruited; 40 patients
with LLV undergoing LP for research purposes and 113 with
clinically indicated LP.
In the 40 patients with LLV, plasma HIV-1 RNA had been
measured a median of five times (IQR 4, 6) in the previous
12 months. HIV-1 RNA had been detected >50 copies/ml on
117 of 198 occasions; median HIV-1 RNA levels during
viraemic episodes was 92 copies/ml (IQR 59, 179). Eight
patients (20 %) reported cognitive symptoms on question-
naire. One patient (3 %) had a score below ten on the
International HIV Dementia scale and one other patient had
a score below eight on the Instrumental Activities of Daily
Living scale. Ten patients (25 %) were anxious and two pa-
tients (6 %) were depressed according to the Hospital Anxiety
and Depression scale.
In the clinical group, 113 patients underwent LP to inves-
tigate cognitive symptoms (n = 50), headache (n = 20),
suspected CNS infection or malignancy (n=18), follow-up
of a previous CNS infection (n=8), abnormal neurological
examinat ion (n = 7), seizure (n = 5) , neuropathy/
radiculopathy (n=2) and others (n=3). On the basis of clini-
cal findings and results of LP CNS infection was excluded in
92/113 patients (81 %). Where CNS infection was proven or
probable, the diagnoses were neurosyphilis (n=4), cryptococ-
cal meningitis (n=2), cryptococcal immune reconstitution in-
flammatory syndrome (n=2), herpes simplex virus type-2
meningitis (n=1), viral radiculopathy (n=1), Ebstein-Barr vi-
rus in CSF of uncertain significance (n=4) and no diagnosis
(n=7). Details of alternative diagnoses in those without CNS
infection were not recorded; symptoms were cognitive
(n=43), headache (n=16), suspected CNS infection or malig-
nancy (n=12), follow-up of a previous CNS infection (n=4),
abnormal neurological examination (n=7), seizure (n=5),
neuropathy/radiculopathy (n=2) and others (n=3). In this
group, 43/113 (38 %) patients had durable HIV-1 RNA sup-
pression for 12 months and no CNS infection. The remaining
70 either had CNS infection (n=21), were not suppressed
(n=26) or were not durably suppressed (n=23).
CSF/plasma HIV-1 RNA discordance
CSF/plasma discordance was found in 7/40 (18 %) patients
with LLV. None of the 43 patients in the clinical group with
durable suppression had discordance. The difference in rate of
discordance between patients with LLV (18 %) and durable
suppression (0 %) was statistically significant, p= 0.005
(Fig. 1). In patients with LLV, there was no difference in mag-
nitude or frequency of HIV-1 RNA detection over the previ-
ous 12 months between those with (n=7) and those without
J. Neurovirol.
(n=33) discordance. There were no significant differences in
the rate cognitive symptoms, International HIV Dementia
Scale results, functional impairment on the Instrumental
Activities of Daily Living scale, or tests of anxiety and depres-
sion. There was a trend to more frequent raltegravir use in
patients with LLV compared to durable suppression (11/40
versus 19/133, p = 0.060), which likely reflects use of
integrase inhibitors to intensify ART in patients with viral
persistence.
In the clinical group, discordance was found in 13/113
(12 %) patients. All discordant patients in this group were
either not suppressed in plasma, not durably suppressed in
plasma or had CNS infection. When combined with the
LLV group, the rate of discordance overall was 20/153
(13 %). Overall HIV-1 RNA levels in plasma and CSF
were directly correlated (Spearman r= 0.51; p< 0.001).
HIV-1 RNA levels were <50 copies/ml in 113/153
(74 %) plasma samples and 115/153 (75 %) CSF sam-
ples. In discordant patients median HIV-1 RNA levels
were 501 copies/ml (IQR 210, 2016) in CSF versus <40
copies/ml (IQR <40,<40) in plasma. Differences in mea-
sured variables among patients with and without CSF/
plasma discordance are shown in Table 1. Patients with
discordance showed a lower nadir (but not current) CD4
cell count and a higher CSF white cell count. Lower
rates of discordance were observed in white MSM com-
pared with black heterosexuals, which may reflect the
higher nadir CD4 cell count in this group (median 173
versus 110 cells/mm3, p= 0.029).
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Fig. 1 CSF HIV-1 RNA in 40 patients with intermittent or persistent
low-level plasma HIV-1 RNA detection in the last year versus 43 patients
from a clinical cohort with durable HIV-1 RNA suppression in the last
year. Filled circles represent discordant samples
Table 1 Univariate analysis of
factors associated with discordant
HIV-1 RNA levels in paired CSF
and plasma samples
CSF/plasma discordance p value
Yes (n= 20) No (n= 133)
Age, median years (IQR) 46 (43, 50) 46 (41, 54) 0.913
Gender male, n (%) 15 (75) 117 (88) 0.156
Risk group/ethnicity, n (%) 0.007
White MSM 7 (35) 80 (60)
Black heterosexual 8 (40) 17 (13)
Other 5 (25) 36 (27)
CD4, median cells/mm3 (IQR)
Nadir 32 (21, 256) 159 (49, 281) 0.030
Current 374 (190, 613) 464 (310, 707) 0.163
Years since HIV diagnosis, median (IQR) 10 (7, 16) 9 (5, 16) 0.833
ART at sampling, n (%) 0.178
PI/r based 14 (70) 74 (55)
NNRTI based 3 (15) 47 (35)
Other 3 (15) 12 (9)
CPE, median (IQR) 7 (7, 10) 7 (6, 8) 0.250
Self reported adherence <95 %, n (%) 2 (10) 12 (9) 1.000
CSF WCC median cells/mm3 (IQR) 11 (<1, 21) <1 (<1, 3) 0.018
CNS infection, n (%) 3 (15) 18 (14) 0.740
Risk group and ethnicity were combined due to co-linearity; 89% ofMSMwere white. CSF white cell count was
tested in 24 (60 %) of LLV patients and all patients in the clinical cohort
MSM men who have sex with men, IVDU intravenous drug user, IQR interquartile range, PI/r ritonavir-boosted
protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside/tide reverse transcrip-
tase inhibitor, RAL raltegravir, MVC maraviroc, CPE CNS penetration effectiveness score 2010
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CSF resistance
CSF samples from 6/7 discordant patients with LLV
underwent sequencing for the detection of HIV-1
RAMs (one patient had insufficient CSF for resistance
testing). All six samples tested showed RAMs; this af-
fected one or more of the ARVs taken at the time of
sampling in 5/6 patients (Table 2). At least one RAM
had been previously identified in plasma in all six
patients.
In the clinical group, 12/13 CSF samples from dis-
cordant patients underwent sequencing (one patient had
insufficient CSF for resistance testing). Five CSF sam-
ples did not amplify despite repeated attempts and one
sample only amplified for the protease gene. Of the six
CSF samples successfully tested, all showed RAMs; this
affected one or more of the ARVs taken at the time of
sampling in all six patients (Table 2). CSF RAMs had
been previously identified in plasma in one patient
(patient 18).
Resistance testing of plasma virus was attempted in
patients 7, 10 and 11. Plasma virus from patients 7 and
10 did not amplify. Plasma from patient 11 showed no
NRTI or NNRTI RAMs; the integrase gene did not
amplify.
Plasma and CSF pharmacokinetics
ARV concentrations in plasma and CSF are shown in Table 3.
No significant differences were observed between those with or
without discordance for any ARVs tested in either CSF or plas-
ma. There were also no significant differences in ARV concen-
trations between those with LLV versus durable suppression. No
associations were observed with CPE score or ART use, either
for individual ARVs or drug class of regimen (Table 1).
Table 2 CSFARV resistance associated mutations (RAMs) in 20 patients with CSF/plasma discordance
HIV-1 RNA copies/ml CSF resistance associated mutations
Patient ID Plasma CSF ART at sampling PI NRTI NNRTI INT
Low-level viraemia group
1 <40 138 TDF/FTC/DRV/r – M184I – –
2 <40 254 EFZ/TDF/FTC Insufficient sample
3 48 2028 DRV/r/TDF/RAL None D67N, K70R, L74V,M184V,
T215Y, K219E
L100IL, K103KN T66I, Y143C
4 78 3234 DRV/r/MVC/ETR None A62V, K65R, M184V None –
5 88 1569 TDF/FTC/DRV/r None M184I None –
6 <40 162 TDF/FTC/DRV/r V82A D67N,M184V, T215Y, K219Q V108I –
7 258 3518 ABC/3TC/DRV/r None L74LV,M184V None –
Clinical cohort
8 40 1038 TDF/FTC/DRV/r None Incomplete testing
9 52 1231 TDF/FTC/RAL/MVC Did not amplify
10 3443 13088 3TC/AZT/EFZ – None V108I, E138A
11 10817 63010 TDF/FTC/RAL – None None L74I
12 <40 400 ABC/3TC/DRV/r/RAL Did not amplify
13 <40 422 TDF/FTC/ATZ/r – T69S, M184I – –
14 <40 335 TDF/FTC/DRV/r Did not amplify
15 <40 162 3TC/AZT/DRV/r/MVC/ETR Insufficient sample
16 <40 129 DRV/r Did not amplify
17 <40 579 ATZ/r/TDF/FTC V82AV M184V, T215I – –
18 <40 1981 DRV/r/RAL/MVC/3TC None M184V V108I N155H
19 <40 195 EFZ/TDF/FTC Did not amplify
20 <40 405 LPV/r/AZT/RAL None None None N155H
RAMs in bold are to ARVs taken at the time of sampling. RAMs in italics have been previously detected in plasma. Patient 9 showed CCR5 tropic virus
in CSF
PI protease inhibitor, NRTI nucleoside/tide reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INT integrase inhibitor,
ATZ atazanavir, DRV darunavir, LPV lopinavir, ETV etravirine, MVC maraviroc, NVP nevirapine, RAL raltegravir, RPV rilpivarine, r ritonavir, EFZ
efavirenz, TDF tenofovir, FTC emtricitabine, 3TC lamivudine, AZT zidovudine
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Discussion
We observed CSF/plasma discordance in 18 % of patients
undergoing a research-based LP for intermittent or continuous
LLV. No discordance was observed in patients with durably
suppressed plasma viral load undergoing clinically indicated
LP. This suggests that a significant proportion of HIV-positive
patients with LLV despite ART may have suboptimal control
of virus replication within the CNS. CSF examination of dis-
cordant patients with LLV revealed RAMs in all samples test-
ed, which related to ART taken at the time of sampling in all
but one. Of note, in these patients, plasma viraemia was gen-
erally too low to perform resistance testing in blood.
One interpretation of these findings could be that ongo-
ing replication of HIV in a CNS sanctuary site results in
seeding to plasma leading to LLV. Alternatively, the ob-
servation of LLV and CSF/plasma discordance may repre-
sent two coinciding aspects of overall suboptimal virolog-
ical suppression. It is of interest that in all cases at least
part of the resistance detected in CSF virus was consistent
with the previous history of failure and older resistance
tests in plasma. This, combined with the observed associ-
ation of discordance with low nadir CD4, suggests that
advanced immune suppression may allow the establish-
ment of a viral reservoir in the CNS that may be only
partially responsive to ART. This virus may then continue
to evolve and develop resistance to some ARVs, for ex-
ample raltegravir, and thus become progressively less sus-
ceptible to suppression than virus in peripheral blood.
LLV with a genetically different virus may originate from
a similar process of incomplete suppression at other sites
such as lymphoid tissue, where drug penetration and ac-
tivity may also vary (Fletcher et al. 2014). Intermittent
reseeding of virus into the CNS during periods of system-
ic replication due to another cause (e.g. non-declared poor
adherence) may also establish compartmentalised CNS in-
fection (Gisslen et al. 2005; Eden et al. 2010). Regardless
of the origin of CSF virus, targeting LP to patients with
unexplained blips or persistent LLV in plasma may repre-
sent a useful strategy in clinical practice and warrants
further investigation. Altering ART based on the resistance
profile of CSF variants has led to clinical improvement
and decrease in CSF HIV-1 RNA in case series
(Canestri et al. 2010; Peluso et al. 2012) and has been
adopted by guidelines as best practice (Mind exchange
2013; Williams et al. 2014). In addition, these findings
add to the evidence suggesting the CNS compartment
must be considered in studies aiming to eradicate HIV
from the periphery.
Screening for cognitive impairment in the LLV group with
a cognitive symptoms questionnaire and International HIV-
Dementia Scale did not reveal associations with CSF/plasma
discordance. The numbers are small and the screening
methods used are insensitive for milder cognitive disorders
(Haddow et al. 2013); nevertheless, these data suggest that
discordant patients were relatively asymptomatic and cogni-
tive deficits were not marked. Whether discordance in this
group has implications for cognitive dysfunction in the longer
term requires clarification in longitudinal studies.
CSF/plasma discordance was present in 12 % of patients
undergoing clinically indicated LP. This rate of discordance is
similar to other reports from clinical settings (Eden et al. 2010;
Rawson et al. 2012). Studies where LP was performed for
research purposes in the absence of clinical indications have
reported lower rates of discordance (Heaton et al. 2010). CSF/
plasma discordance overall was not associated with ART at
sampling, CPE score or ARV concentrations in plasma or
CSF, but was associated with nadir CD4 cell count. This sug-
gests the presence of HIV in the CNS relates to a longer du-
ration of viral replication and a lower immune status, consis-
tent with the hypothesis of CNS viral persistence discussed
above. In cross sectional studies, nadir CD4 has been consis-
tently associated with cognitive impairment (Robertson et al.
2007; Heaton et al. 2010). It has not been clear whether this
Table 3 Antiretroviral concentrations in CSF and plasma
n Drug concentration (ng/ml)
Geo mean 95 % CI
Plasma
Tenofovir 62 89.5 73.1–110.7
Emtricitabine 65 187.9 136.5–264.9
Lamivudine 24 383.7 225.4–688.7
Darunavir 55 2971.7 2393.3–3715.4
Atazanavir 19 729.5 418.8–1339.7
Lopinavir 3 8570.4 7798.3–9440.6
Ritonavir 15 116.1 55.7–277.3
Efavirenz 27 1741.8 1349.0–2269.9
Nevirapine 10 4226.7 2691.5–6807.7
Etravirine 4 269.2 64.4–1836.5
Rilpivarine 4 68.1 36.0–144.2
Maraviroc 8 172.2 88.9–367.3
Raltegravir 11 413.9 174.1–1135.0
CSF
Darunavir 54 35.2 27.8–45.4
Atazanavir 20 6.4 4.1–11.5
Lopinavir 3 9.6 4.1–37.3
Efavirenz 26 14.7 11.4–19.4
Nevirapine 12 1559.6 1127.2–2197.9
Maraviroc 9 6.5 2.75–31.6
Raltegravir 14 25.9 18.1–38.7
Geometric mean and 95 % confidence interval for drug concentrations in
plasma and CSF. No significant associations were observed with CSF/
plasma discordance
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association is due to a legacy effect of CNS damage sustained
prior to ART initiation or whether it represents an ongoing
CNS inflammatory process set up during advanced immunosup-
pression. In our study, all discordant CSF samples successfully
tested showed RAMs. Overall RAMs were demonstrated in 12
CSF samples including NRTI RAMs in eight of ten on NRTIs at
sampling and raltegravir RAMs in all four patients on raltegravir
at sampling. Other work on this cohort has demonstrated raised
inflammatory cytokines in CSF of patients with discordance,
even at relatively low levels (Nightingale et al. 2016).
There are a number of limitations to our study.
Selecting controls from patients undergoing clinically
indicated LP was not ideal; however, as clinical cohorts
have shown higher rates of discordance than those un-
dergoing LP for research purposes, this risked producing
a false negative rather than false positive result. We
assessed adherence by self-report which may not be
reliable in all patients. Of note, there were no observed
differences in measured plasma ARV concentrations be-
tween those with and without discordance suggesting
that adherence was similar between groups, at least in
terms of very recent ART use. Differences in the rate of
viral decay between compartments in those recently
starting or changing ART could have led us to identify
some with discordance that did not have true
compartmentalisation (Schnell et al. 2009). Discordant
patients in the LLV group had been on ART for many
years; however, recent ART modification was not an
exclusion and could have contributed. In the clinical
group, we did not routinely collect details of ART his-
tory and cannot exclude that this was the source of
discordance in some patients. Our analysis of factors
related to discordance involved grouping the LLV group
with the more heterogeneous clinical group, some of
which were not suppressed and/or had CNS infection.
This group is reflective of patients undergoing CSF ex-
amination in the UK clinical practice and may be more
transferable to the clinical environment. Indeed studies
recruiting asymptomatic patients for research LP, such
as the CHARTER cohort in the USA, found few cases
of discordance despite sampling large patient popula-
tions (Heaton et al. 2010). Our ability to find associa-
tions of discordance with ARV concentrations in CSF
and plasma was limited by few measurements for some
drugs. In addition, ARV concentrations in CSF may not
be the most important factor determining effectiveness
of ART in the CNS (Calcagno et al. 2014), in particular
ARV concentrations in CSF may not reflect levels with-
in perivascular macrophages, the critical target of HIV
in the brain (McArthur et al. 2010). Our finding of no
link between CPE score and discordance should also be
interpreted with caution as our study was not designed
to look for such an association and may be confounded
by prescriber bias, whereby patients with CNS problems
are more likely to receive an ART regimen with a
higher CPE score (Garvey et al. 2011).
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